Huaren Pharmaceutical Co Ltd (300110) — Strategic Asset Allocation Index
Huaren Pharmaceutical Co Ltd (300110) has a Strategic Asset Allocation Index of 41.4% as of June 2023. Strategic assets (PP&E of CN¥1.10 Billion plus long-term investments of CN¥-) total CN¥1.10 Billion, measured against net assets of CN¥2.66 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Huaren Pharmaceutical Co Ltd (300110) net asset quality to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Huaren Pharmaceutical Co Ltd Strategic Asset Allocation Index (2007–2022)
This chart shows how Huaren Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 16 annual periods from 2007 to 2022. As of June 2023, the index stands at 41.4%, representing strategic assets of CN¥1.10 Billion against net assets of CN¥2.66 Billion CNY. For live market cap and overall valuation, see market cap of Huaren Pharmaceutical Co Ltd.
Annual Strategic Asset Allocation Index for Huaren Pharmaceutical Co Ltd (2007–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Huaren Pharmaceutical Co Ltd from 2007 to 2022, covering 16 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Huaren Pharmaceutical Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 43.8% | CN¥1.14 Billion | CN¥1.14 Billion | CN¥- | CN¥2.60 Billion | ▼ -6.1 pp |
| 2021 | 49.9% | CN¥1.22 Billion | CN¥1.22 Billion | CN¥- | CN¥2.44 Billion | ▼ -4.7 pp |
| 2020 | 54.6% | CN¥1.27 Billion | CN¥1.27 Billion | CN¥- | CN¥2.33 Billion | ▲ +2.5 pp |
| 2019 | 52.2% | CN¥1.17 Billion | CN¥1.17 Billion | CN¥- | CN¥2.25 Billion | ▼ -4.4 pp |
| 2018 | 56.6% | CN¥1.27 Billion | CN¥1.27 Billion | CN¥6.60 Million | CN¥2.25 Billion | ▼ -30.3 pp |
| 2017 | 86.9% | CN¥1.34 Billion | CN¥1.34 Billion | CN¥- | CN¥1.55 Billion | ▼ -5.0 pp |
| 2016 | 91.8% | CN¥1.40 Billion | CN¥1.40 Billion | CN¥- | CN¥1.53 Billion | ▲ +1.1 pp |
| 2015 | 90.7% | CN¥1.31 Billion | CN¥1.31 Billion | CN¥- | CN¥1.44 Billion | ▲ +4.5 pp |
| 2014 | 86.2% | CN¥1.28 Billion | CN¥1.28 Billion | CN¥- | CN¥1.48 Billion | ▲ +3.2 pp |
| 2013 | 83.0% | CN¥1.21 Billion | CN¥1.21 Billion | CN¥- | CN¥1.46 Billion | ▼ -0.3 pp |
| 2012 | 83.3% | CN¥1.12 Billion | CN¥1.12 Billion | CN¥- | CN¥1.34 Billion | ▲ +34.0 pp |
| 2011 | 49.3% | CN¥587.00 Million | CN¥587.00 Million | CN¥- | CN¥1.19 Billion | ▲ +12.1 pp |
| 2010 | 37.2% | CN¥410.46 Million | CN¥410.46 Million | CN¥- | CN¥1.10 Billion | ▼ -73.0 pp |
| 2009 | 110.2% | CN¥345.83 Million | CN¥345.83 Million | CN¥- | CN¥313.80 Million | ▼ -20.9 pp |
| 2008 | 131.1% | CN¥289.76 Million | CN¥289.76 Million | CN¥- | CN¥221.03 Million | ▲ +33.2 pp |
| 2007 | 97.9% | CN¥180.85 Million | CN¥180.85 Million | CN¥- | CN¥184.68 Million | — |